COMPANY PROFILE

IMBiologics

Explore full profile

Research and Development of Antibody Therapeutics

Suwon, South KoreaFounded 2020Biotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Total funding $50–100M Disclosed equity funding

Unlock exact values

About IMBiologics

IMBiologics specializes in the research and development of innovative immunomodulatory antibody therapeutics aimed at treating autoimmune diseases and cancer. The company operates in the biopharmaceutical sector, focusing on creating novel drugs that help restore homeostasis, the body's natural balance. IMBiologics serves a global clientele, including healthcare providers and patients in need of advanced treatments for complex diseases. The business model revolves around leveraging proprietary platform technology and in-licensed drug candidates to accelerate drug development. Revenue is generated through licensing deals, partnerships, and the commercialization of its therapeutic products. The company has successfully raised significant funding, including a 4B KRW seed round and a 13B KRW Series A financing round, to support its R&D activities and growth initiatives.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Suwon, South Korea
Open positions: 1
Dealroom signal: 21.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Oct 2025	$35M	$168M	Partners Investment · K2 Investment Partners · Korea Development Bank · QUAD Ventures	↗
SERIES BOther financing	Jul 2023	$17M	$67M	Partners Investment · Atinum Investment · K2 Investment Partners · Wooshin Venture Investment	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

IMBiologics website traffic

Latest recorded traffic for IMBiologics is 4.1K monthly website visits, down 59% over the last three months.

Latest monthly visits4.1K 3-month web change-59%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NGNest GenomicsMaking genetic testing mainstream and integrated into patient care is difficult, Â Nest makes it easy	New York City, United States	Operational	17	$11M	$34M
ATArctic TherapeuticsTransforming drug discovery and development by harnessing the power of applied of genomics	Reykjavík, Iceland	Operational
OMOmicsChartPatient-centric cancer data and analytics platform for translational cancer biologists	Cardiff, United Kingdom	Operational
RBRealSeq Biosciences“... when working with low amounts of RNA, RealSeq was the only method that preserved high levels of complexity."	Santa Cruz, United States	Operational
ASAston SciTherapeutic cancer vaccines for oncology and immunology	Seoul, South Korea	Operational
DBDirect biologicsInnovative regenerative biologic products leveraging extracellular vesicles and placental-based allografts for advanced therapies	Oakville, United States	Operational
DADatabiologicsData platform tracking real-world regenerative medicine outcomes	East Hanover, United States	Operational
PBPalisade BioLate-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage	Carlsbad, United States	Operational